PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

NCT00766324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone Refractory Prostate Cancer

Interventions

DRUG: PHA-739358
DRUG: PHA-739358

Sponsor

Nerviano Medical Sciences